Apatinib Exhibits Anti-Leukemia Activity in Preclinical Models of Acute Lymphoblastic Leukemia

Manman Deng,Jie Zha,Zhiwu Jiang,Xian Jia,Yuanfei Shi,Peng Li,Xiao Lei Chen,Zhihong Fang,Zhiqiang Du,Bing Xu
DOI: https://doi.org/10.1186/s12967-018-1421-y
IF: 8.44
2018-01-01
Journal of Translational Medicine
Abstract:Acute lymphoblastic leukemia (ALL) is a clonal malignant disorder characterized by an uncontrolled proliferation of immature B or T lymphocytes. Extensive studies have suggested an involvement of angiogenesis signaling in ALL progression and resistance to treatment. Thus, targeting angiogenesis with anti-angiogenic drugs may be a promising approach for ALL treatment. In this study, we investigated the effectiveness of Apatinib, a novel receptor tyrosine kinase inhibitor selectively targeting VEGFR-2 in ALL cells.
What problem does this paper attempt to address?